Metformin for insulin resistance and weight loss: what the evidence shows

Insulin resistance quietly drives the progression toward type 2 diabetes, metabolic syndrome and cardiovascular disease, and one medication comes up again and again in conversations about it: metformin. It also comes up in a second, noisier conversation, about weight loss, where some sources promise dramatic results and others insist it barely moves the needle.

Metformin has been studied for decades, first as a type 2 diabetes treatment and increasingly earlier in the metabolic disease spectrum. This guide covers both questions in one place: how metformin works on insulin resistance, what the clinical trials show, how much weight people realistically lose on it, how it compares with GLP-1 medications, the side effects to know and who should discuss it with a clinician.

What is insulin resistance?

Insulin resistance is a metabolic dysfunction in which cells in skeletal muscle, fat tissue and the liver stop responding properly to insulin. Normally, insulin unlocks glucose uptake into cells, suppresses glucose output from the liver and promotes energy storage. When that signaling is impaired, the pancreas compensates by releasing more and more insulin to get the same effect, a state called compensatory hyperinsulinemia. Skeletal muscle accounts for roughly 70% of insulin-stimulated glucose disposal; when muscle becomes resistant, GLUT4-mediated glucose uptake falls and excess glucose is redirected to the liver, accelerating fat accumulation and deepening resistance.

Over time, often across 10 to 15 years, the beta cells that sustain this extra insulin output begin to falter. Blood glucose drifts upward, moving from insulin resistance to prediabetes and eventually to type 2 diabetes. Insulin resistance is estimated to underlie 70 to 90% of type 2 diabetes cases.

It rarely travels alone. Insulin resistance is a central feature of metabolic syndrome (central obesity, high blood pressure, high triglycerides and low HDL cholesterol). It is present in an estimated 50 to 70% of people with polycystic ovary syndrome (PCOS), where it worsens androgen excess and ovulatory problems, and it is tightly linked to fatty liver disease (now often called metabolic dysfunction-associated steatotic liver disease). Across all of these, elevated cardiovascular risk is a shared thread, driven by the inflammatory environment that insulin resistance promotes.

There is also a diagnostic gap. No single FDA-approved test is designated to diagnose insulin resistance, and no medication carries an FDA indication solely for treating it. Clinicians rely on surrogate markers such as HOMA-IR, the triglyceride-to-HDL ratio and risk factors like visceral obesity and family history. That is why metformin is used for conditions associated with insulin resistance, such as type 2 diabetes or prediabetes, rather than for insulin resistance as a defined clinical target. Our overview of insulin resistance covers the condition itself in more depth.

What metformin is and how it is used

Metformin is an oral biguanide, first synthesized in 1922 from guanidine compounds found in Galega officinalis (goat’s rue). It entered clinical use for diabetes in Europe in the 1950s and received FDA approval in 1994 for type 2 diabetes, reaching the US market in 1995. Roughly 85.7 million US prescriptions were written for it in 2023 alone. Current clinical guidelines reviewed by the AAFP continue to support it as a first-line option alongside lifestyle change.

Metformin is best described as an insulin sensitizer, not an insulin secretagogue. Unlike sulfonylureas, which push the pancreas to release more insulin, metformin improves the body’s ability to use the insulin it already makes. Because it does not trigger extra insulin secretion, it carries a low risk of hypoglycemia on its own and does not add to the high insulin levels that often accompany insulin resistance.

Beyond type 2 diabetes, clinicians commonly consider metformin off-label for prediabetes (especially with obesity or a history of gestational diabetes), PCOS and aspects of metabolic syndrome, as the DrugBank clinical profile reflects. It is not approved as a weight-loss medication; any weight effect is secondary. Whether it suits a particular person depends on a licensed prescriber’s review of kidney function, contraindications, current medications and the full clinical picture.

How metformin works on insulin resistance

Metformin’s effects come from several coordinated mechanisms rather than one action.

The liver: suppressing glucose output

In insulin resistance, the liver often keeps producing glucose through gluconeogenesis even when blood glucose is already high. Metformin inhibits mitochondrial complex I in liver cells, raising the AMP-to-ATP ratio and activating AMP-activated protein kinase (AMPK). AMPK then suppresses key gluconeogenic enzymes, including PEPCK and glucose-6-phosphatase. This hepatic effect accounts for the majority of metformin’s glucose-lowering activity, and over time it also appears to reduce fat accumulation in the liver.

Skeletal muscle: better glucose uptake

Through AMPK activation in muscle, metformin promotes GLUT4 transporter activity at the cell surface, helping glucose enter muscle cells even when insulin signaling is reduced. Studies of whole-body glucose disposal show improvements of approximately 20% with chronic use, supporting its classification as a true insulin sensitizer.

Broader metabolic effects of AMPK

AMPK activation also lowers malonyl-CoA, which increases fatty acid burning in mitochondria, suppresses new fat production through SREBP-1c, and upregulates PGC-1 alpha, a regulator of mitochondrial biogenesis and quality control. Together these reduce lipotoxicity and oxidative stress, two drivers that keep insulin resistance going.

The gut

Metformin concentrations in the jejunum can reach 30 to 300 times those in plasma, making the gut a significant site of action. Metformin modestly slows carbohydrate absorption, stimulates GLP-1 secretion from intestinal L-cells and shifts gut microbiota composition, including species involved in bile acid metabolism and short-chain fatty acid production.

The net effect: lower insulin demand

By reducing liver glucose output and improving glucose disposal, metformin lowers the amount of insulin the pancreas must produce, without stimulating insulin secretion directly. That profile is why it can interrupt the underlying metabolic dysfunction rather than simply mask high blood sugar.

What the clinical evidence shows

The Diabetes Prevention Program

The Diabetes Prevention Program (DPP) randomized more than 3,200 adults with prediabetes. Over a mean 2.8 years, metformin (850 mg twice daily) produced a 31% reduction in progression to type 2 diabetes versus placebo, a number needed to treat of roughly 14 over three years. The intensive lifestyle arm, targeting about 7% weight loss and 150 minutes of moderate activity per week, achieved a 58% reduction, with a number needed to treat closer to seven. Lifestyle change was nearly twice as effective as the medication alone, and any evidence-based approach treats it as foundational.

Long-term durability: the DPPOS

The Diabetes Prevention Program Outcomes Study followed participants for at least 15 years and, in later analyses, beyond 20. The NIDDK’s summary confirms that benefits persisted but attenuated: at 15 years, the lifestyle group kept about a 27% reduction in diabetes incidence and the metformin group about 18%. Median diabetes-free survival was extended by an estimated 3.5 years with lifestyle and 2.5 years with metformin. Cumulative incidence at year 15 was around 55% (lifestyle), 56% (metformin) and 62% (placebo). Durable benefit depends on sustained effort, not a finite course.

Who benefited most

Metformin’s benefit was most pronounced in women with a history of gestational diabetes (some analyses showed reductions approaching 41% at longer follow-up), adults aged 25 to 44 and people with a BMI of 35 or higher. In older adults and women without gestational diabetes history, the advantage over placebo was modest or negligible. The same drug produces materially different results depending on the person.

PCOS

Systematic reviews and meta-analyses document improvements in fasting insulin, HOMA-IR and glucose tolerance with metformin in women with PCOS, including adolescents with obesity, along with research into ovulatory function and fertility outcomes. Benefits are greater with higher BMI and documented insulin resistance.

A 2025 caveat in type 1 diabetes

A 2025 randomized, placebo-controlled trial in Nature Communications added 26 weeks of metformin to insulin in adults with type 1 diabetes and found no improvement in clamp-measured insulin resistance in liver, muscle or fat, although total daily insulin dose fell. The mechanism of insulin resistance in type 1 diabetes differs from prediabetes or metabolic syndrome, and the trial is a reminder that efficacy is population-specific.

Metformin and weight loss: what to realistically expect

Weight change on metformin is real but modest, secondary to its main purpose, and highly dependent on adherence and how insulin resistant a person is.

Why metformin can affect weight

Several pathways appear to contribute, none of them dramatic on its own:

• Appetite. Reduced appetite and calorie intake are thought to be the main driver. Contributing pathways include effects on hypothalamic appetite centers, satiety hormones and increased secretion of GDF15, a stress-related hormone that signals reduced hunger. Older dose-response studies linked doses around 1,700 mg daily with lower hunger ratings and intake.
• Lac-Phe. Research published in 2024 in collaboration with Stanford Medicine identified metformin as a stimulator of N-lactoyl-phenylalanine (lac-phe), the same appetite-suppressing metabolite the body makes during vigorous exercise. When lac-phe production was genetically blocked in mice, metformin’s weight effects were largely abolished. This is still an active area of research.
• Insulin and fat storage. Chronically high insulin promotes fat storage. By improving insulin sensitivity, metformin may reduce that storage signal in people for whom insulin resistance is a meaningful factor.
• Gut effects. GI effects and microbiome shifts may also reduce intake, though their direct contribution to weight is still being studied.

Taken together, these pathways explain why metformin is associated with modest, adherence-dependent weight changes rather than substantial loss.

How much weight people lose

In the DPP, participants on metformin lost an average of about 2.1 kg (4.6 lb) over 2.8 years, compared with negligible change on placebo and about 5.6 kg with intensive lifestyle intervention. Meta-analyses of trials lasting at least six months, mostly at doses above 1,500 mg per day, report additional weight loss of about 1.1 to 3.3 kg versus placebo or comparators, with BMI reductions of roughly 1 to 1.3 units. Effects tend to be larger with higher baseline BMI or greater insulin resistance.

Some highly responsive people with significant insulin resistance lose 3 to 6% of body weight within about two months, and those numbers circulate widely on social media. They reflect a narrow subset. Real-world averages consistently fall in the 2 to 5 kg range over several months, and starting with outlier expectations can erode the motivation and adherence that long-term results depend on.

The underappreciated strength: keeping weight off

Metformin’s stronger signal may be maintenance. Among DPP participants who lost at least 5% of body weight in the first year, continued metformin use was associated with a mean 6.2% loss from baseline across years 6 through 15, compared with 3.7% in the lifestyle group and 2.8% with placebo among initial responders. DPP long-term follow-up shows the same pattern: adherence predicted better maintenance.

What happens when you stop

When metformin is stopped, its effects on insulin sensitivity, appetite and gut hormones do not persist. Published DPP adherence data show the weight benefits were adherence-dependent throughout, and erosion tracked closely with lapses in use. This is not unique to metformin; metabolic conditions that respond to treatment tend to return when treatment is withdrawn.

Where metformin fits in current guidelines

The ADA Standards of Care in Diabetes 2026 continue to position metformin as a commonly recommended first-line option for most adults with type 2 diabetes who lack comorbidities that call for a different choice. Its case rests on a decades-long safety record, low-cost generic availability, weight neutrality or modest loss, no intrinsic hypoglycemia risk as monotherapy and landmark prevention data. For high-risk adults with prediabetes, guidelines also support it to reduce progression, particularly with a BMI of 35 or higher or a history of gestational diabetes.

GLP-1 receptor agonists and SGLT2 inhibitors are now prioritized alongside or ahead of metformin for people with established cardiovascular disease, heart failure, chronic kidney disease or significant obesity, because of organ-protective benefits beyond glucose control. Guidelines no longer require metformin failure before starting them, and metformin may be continued in combination unless kidney function limits it. In cost-sensitive settings or where cardiorenal risk is not the main driver, metformin retains a strong and well-supported role. Every credible framework calls for individualized decisions by a licensed prescriber.

Metformin vs. GLP-1 receptor agonists

Different mechanisms

Metformin works mainly in the liver and muscle, through AMPK, with modest effects on appetite. GLP-1 receptor agonists mimic the gut hormone GLP-1: they trigger glucose-dependent insulin release, suppress glucagon, slow gastric emptying and act on brain satiety centers to reduce appetite. There is some overlap, since metformin may modestly raise the body’s own GLP-1 levels.

Very different weight outcomes

Metformin is generally weight-neutral or associated with modest loss. GLP-1 receptor agonists have produced average body weight losses of 13 to 21% or more with certain agents at higher doses over extended treatment, with dual incretin agonists showing particularly strong results. That matters for insulin resistance because visceral fat is a major driver of insulin signaling dysfunction.

Organ protection

Large cardiovascular outcome trials of GLP-1 receptor agonists have shown reductions in major adverse cardiovascular events, heart failure hospitalizations and kidney outcomes in higher-risk patients, with pooled hazard ratios of roughly 0.82 to 0.87 for cardiovascular events. As a clinical comparison notes, metformin retains value but lacks the same depth of organ-protective trial evidence in high-risk populations.

Practical trade-offs and combination use

Metformin is oral, has decades of clinical use, a well-characterized safety record and generic pricing at a fraction of the cost of injectable GLP-1 therapies, which can run into thousands of dollars a year without insurance coverage. The two are increasingly used as complementary rather than competing options: metformin can serve as an adjunct within a GLP-1 program or as a transitional support, and combination approaches are supported when clinically appropriate. Neither is right for everyone; the choice depends on glycemic status, kidney function, cardiovascular risk, weight, comorbidities and goals, assessed by a clinician.

Side effects, safety and who should not take it

• GI effects (nausea, loose stools, gas, bloating, abdominal discomfort) are the most common and usually mild and transient, most likely early on. Starting low (typically 500 mg once or twice daily with meals), titrating gradually and taking it with food all help. A 2026 prospective cohort study found 24.5% of extended-release users reported GI side effects at six months, versus 45.2% on immediate-release.
• Vitamin B12. Long-term use is associated with reduced B12 absorption in some people, so periodic monitoring is standard.
• Lactic acidosis is rare (approximately 0.03 cases per 1,000 patient-years) but serious. Metformin is contraindicated with an eGFR below 30 mL/min/1.73 m², and liver impairment, severe heart failure and other low-oxygen states, dehydration and heavy alcohol use raise risk.
• Interactions. Alcohol increases lactic acidosis risk; combining with insulin or other glucose-lowering drugs raises hypoglycemia potential; some supplements, such as chromium, may add to glucose-lowering effects.

A prescriber reviews kidney and liver labs, the full medication list and comorbidities before starting, and continues to monitor kidney function and B12 over time.

Berberine and supplements: honest calibration

Berberine is often mentioned alongside metformin because it also activates AMPK, and some shorter studies show modest improvements in fasting glucose, post-meal glucose and insulin resistance markers. But its evidence base is far thinner: most studies are smaller, shorter and methodologically varied, while metformin has decades of large randomized trials, long-term safety surveillance and FDA approval for type 2 diabetes. Berberine is regulated as a dietary supplement, with no pre-market FDA review of efficacy, and product quality varies. Our review of berberine side effects covers the safety side, and our piece on Jardiance side effects compares another class of diabetes medication.

Under the Dietary Supplement Health and Education Act (DSHEA), supplements may make structure/function claims such as “supports healthy glucose metabolism,” but cannot claim to diagnose, treat, cure or prevent insulin resistance or any other disease. Magnesium, inositol, alpha-lipoic acid and chromium have also been studied for metabolic support. Within a program built on nutrition, activity and sleep, supplements can play a supportive role; they do not substitute for clinically evaluated treatment when it is warranted.

Why metformin works best inside a broader program

The DPP made the point directly: lifestyle produced more weight loss (about 5.6 kg vs 2.1 kg) and more diabetes prevention (58% vs 31%) than metformin, and its benefits endured more robustly over 15 to 21 years. Metformin’s contribution is meaningful, but it is amplified by deliberate behavioral and nutritional change.

Because metformin improves insulin sensitivity and lowers liver glucose output, lower-glycemic, higher-fiber eating complements it: fewer refined carbohydrates, more whole foods, adequate protein and vegetables. Research comparing metformin plus dietary change against either alone consistently favors the combination. Our insulin resistance diet guide covers the food side.

No medication builds habits, manages stress or improves sleep. Behavioral support improves long-term adherence and maintenance in obesity and diabetes prevention trials. Elara’s physician-supervised programs are built on this model: licensed clinicians conduct individualized evaluations (including fasting glucose, insulin, HbA1c, comorbidities and contraindications), certified health coaches provide ongoing support across nutrition, movement and habits, and physician-formulated supplement packs are available as an optional add-on. Telehealth is not right for everyone; people who need in-person diagnostics, have certain contraindications or have acute symptoms may need a different care setting, and eligibility for any medication is always determined by a licensed prescriber.

Frequently asked questions

Is metformin approved for insulin resistance?

No. Metformin is FDA-approved for type 2 diabetes. No medication is FDA-approved specifically for insulin resistance; metformin is used off-label for related conditions such as prediabetes and PCOS when a prescriber judges it appropriate.

Does metformin cause weight loss?

Modestly, in many people. Trials show about 2.1 kg on average in the DPP and 1.1 to 3.3 kg more than placebo in meta-analyses, with larger effects in people with higher BMI or more insulin resistance. It is not approved as a weight-loss drug, and use for weight alone without diabetes is off-label.

How long before weight effects are noticeable?

When they occur, meaningful changes typically emerge over several months of consistent use at therapeutic doses. Short-term dramatic results seen online are not supported by the evidence, and benefits fade if the medication is stopped.

Can metformin prevent type 2 diabetes?

In the DPP it reduced progression from prediabetes by 31% versus placebo over about 2.8 years, with long-term follow-up showing roughly 2.5 additional diabetes-free years. Intensive lifestyle change did better, at 58%.

Is metformin used for PCOS?

Yes, off-label, particularly when insulin resistance is a factor. It can improve insulin sensitivity, menstrual regularity and androgen levels, and international guidelines suggest considering it alongside lifestyle changes for women with a BMI of 25 kg/m² or higher. Weight effects in PCOS are modest, with meta-analyses reporting mean BMI reductions of about 0.5 kg/m².

How does metformin compare with GLP-1 medications for weight loss?

GLP-1 receptor agonists produce substantially more weight loss and have stronger cardiovascular and kidney outcome data. Metformin is oral, inexpensive and long established. They act on different pathways and are sometimes used together under clinical supervision.

What are the most common side effects?

GI effects such as nausea, loose stools and bloating, usually early and transient. Gradual titration, taking it with food and extended-release forms reduce them. Long-term users need periodic B12 checks, and kidney function determines whether it is safe.

Key takeaways

• Metformin is an insulin sensitizer that lowers liver glucose output and improves muscle glucose uptake through AMPK, reducing insulin demand without stimulating insulin secretion.
• In the DPP it cut progression from prediabetes to type 2 diabetes by 31%, versus 58% for intensive lifestyle change; benefits persisted but narrowed over 15+ years.
• Weight loss is modest, around 2 kg on average, with its clearest strength in helping early responders maintain loss over years.
• GLP-1 receptor agonists produce far greater weight loss and organ-protective benefits; the two can be complementary.
• Eligibility, dosing and monitoring belong with a licensed prescriber who reviews kidney function, labs and your full health picture.

Sources

• Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (Diabetes Prevention Program). New England Journal of Medicine
• NIDDK. Diabetes Prevention Program (DPP)
• Diabetes Prevention Program Research Group. Long-term safety, tolerability and weight loss associated with metformin in the DPP Outcomes Study; also in Diabetes Care
• DPP long-term follow-up (PMC)
• Long-term weight loss with metformin or lifestyle intervention in the DPP (GWU Biostatistics Center)
• Meta-analysis of metformin and weight, Diabetes, Obesity and Metabolism
• Metformin mechanisms in human obesity and weight loss (PMC)
• Metformin and AMPK mechanisms (PMC)
• AMPK and mitochondrial biogenesis (PMC)
• Metformin, StatPearls (NCBI Bookshelf)
• Insulin resistance, StatPearls (NCBI Bookshelf)
• Cleveland Clinic: Insulin resistance
• DrugBank: Metformin
• American Family Physician editorial on metformin
• American Diabetes Association. Standards of Care in Diabetes 2026: Pharmacologic approaches to glycemic treatment
• Diabetes in Control: Metformin in 2026
• HealthCentral: Metformin vs GLP-1 receptor agonists
• Drugs.com: How metformin and GLP-1 drugs compare

Last updated October 12, 2026.